People
The COO of Seattle Genetics, Eric Dobmeier, is leaving the company to helm Silverback Therapeutics.
There’s been a major shakeup in the executive team at Human Longevity.
There are some changes taking place in the C-suites at Shire.
The company’s head of Development, Joerg Moeller, is taking the reins of the company’s new R&D program.
Ms. Kinjerski is a senior business development executive with more than 17 years of experience in the biopharmaceutical industry,
Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.
Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx.
Mr. Hartman overviewed the Company’s Anti-Cancer R&D program and discussed his intent to find a licensee for the technology or investment partner to complete the development of this very promising anti-cancer antibody drug.
A look at six bay area-based VCs who are creating a lot of value in biotech.
PRESS RELEASES